Cardinal Health, Inc.
CAH| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $222.58B | $226.83B | $204.98B | $181.33B | $162.47B | $152.92B | $145.53B | $136.81B |
| Cost of Revenue | $214.41B | $219.41B | $198.09B | $174.84B | $155.69B | $146.05B | $138.70B | $129.63B |
| Gross Profit | $8.17B | $7.41B | $6.89B | $6.48B | $6.78B | $6.87B | $6.83B | $7.18B |
| Gross Margin | 3.67% | 3.27% | 3.36% | 3.58% | 4.17% | 4.49% | 4.70% | 5.25% |
| Operating Expenses | $5.89B | $6.17B | $6.14B | $7.09B | $6.31B | $10.97B | $4.77B | $7.05B |
| Operating Income | $2.27B | $1.24B | $752.00M | $-607.00M | $472.00M | $-4.10B | $2.06B | $126.00M |
| Operating Margin | 1.02% | 0.55% | 0.37% | -0.33% | 0.29% | -2.68% | 1.42% | 0.09% |
| Net Income | $1.56B | $852.00M | $330.00M | $-938.00M | $611.00M | $-3.69B | $1.36B | $256.00M |
| Net Margin | 0.70% | 0.38% | 0.16% | -0.52% | 0.38% | -2.41% | 0.94% | 0.19% |
| EPS (Basic) | $6.48 | $3.48 | $1.26 | $-3.34 | $2.09 | $-12.60 | $4.54 | $0.82 |
| EBITDA | $3.11B | $1.96B | $1.44B | $55.00M | $1.29B | $-2.62B | $3.04B | $1.13B |
| Stock Option Compensation Expense | $244.00M | $121.00M | $96.00M | $0.00 | $89.00M | $90.00M | $82.00M | $85.00M |
| Price To Earnings Ratio | 25.94 | 28.11 | 74.80 | -15.55 | 27.28 | -4.14 | 10.47 | 59.70 |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | $40.49B | $23.95B | $24.68B | $14.58B | $16.67B | $15.29B | $14.27B | $15.28B |
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $53.12B | $45.12B | $43.35B | $43.88B | $44.45B | $40.77B | $40.96B | $39.95B |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $55.76B | $48.33B | $46.31B | $44.58B | $42.66B | $38.97B | $34.63B | $33.89B |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $-2.78B | $-3.21B | $-2.96B | $-709.00M | $1.79B | $1.79B | $6.33B | $6.06B |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $-2.78B | $-3.21B | $-2.96B | $-709.00M | $1.79B | $1.79B | $6.33B | $6.06B |
| Total Liabilities & Stockholders Equity | $53.12B | $45.12B | $43.35B | $43.88B | $44.45B | $40.77B | $40.96B | $39.95B |
| Book Value Per Share | $-10.93 | $-13.11 | $-11.33 | $-2.53 | $6.14 | $6.12 | $21.10 | $19.36 |
| Tangible Book Value Per Share | $-61.46 | $-39.44 | $-34.64 | $-29.87 | $-28.42 | $-32.37 | $-18.26 | $-19.71 |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 2.94% | 1.89% | 0.76% | -2.14% | 1.37% | -9.06% | 3.33% | 0.64% |
| Return on Equity | -56.13% | -26.52% | -11.16% | 132.30% | 34.12% | -206.43% | 21.54% | 4.23% |
| Return on Invested Capital | 11.37% | 8.80% | 3.58% | -4.33% | 2.65% | -23.38% | 9.28% | -0.79% |
| Quick Ratio | 0.50 | 0.56 | 0.52 | 0.57 | 0.60 | 0.54 | 0.54 | 0.53 |
| Current Ratio | 0.94 | 0.98 | 1.00 | 1.08 | 1.12 | 1.10 | 1.07 | 1.07 |
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $1.56B | $852.00M | $330.00M | $-938.00M | $611.00M | $-3.69B | $1.36B | $256.00M |
| Depreciation | $790.00M | $710.00M | $692.00M | $692.00M | $783.00M | $913.00M | $1.00B | $1.03B |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $2.40B | $3.76B | $2.84B | $3.12B | $2.43B | $1.96B | $2.72B | $2.77B |
| Capital Expenditures | $547.00M | $511.00M | $481.00M | $387.00M | $400.00M | $375.00M | $328.00M | $384.00M |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | $494.00M | $499.00M | $525.00M | $559.00M | $573.00M | $569.00M | $577.00M | $581.00M |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | $765.00M | $750.00M | $2.00B | $1.00B | $200.00M | $350.00M | $600.00M | $550.00M |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | $1.85B | $3.25B | $2.36B | $2.73B | $2.03B | $1.58B | $2.39B | $2.38B |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Show 12 more stories
Insider Trading
View AllCompany
About the company
Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.